BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

With ex-Gilead BD head Jeremy Bender on board as CEO, Canaan-incubated pediatric cancer company Day One aims to expand its in-licensed pipeline and explore partnering opportunities with larger companies. “My background complements both of those...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BioCentury | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline...
BioCentury | Aug 15, 2019
Distillery Techniques

Targeting a KRAS allosteric site with designed ankryin repeat proteins (DARPins)

...DARPins bound KRAS G12V with Kd values of about 10 and 30 nM, and blocked CRAF (RAF1)...
BioCentury | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
BioCentury | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

...Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF...
...patient-derived KRAS- and p53-mutant PDAC cells lines, two shRNAs against EGFR plus two shRNAs against CRAF...
...PDAC, systemic knockout of EGFR and CRAF decreased tumor size compared with normal EGFR and CRAF...
BioCentury | Jan 4, 2019
Company News

Xynomic returns to Boehringer for second cancer candidate

Xynomic Pharmaceuticals (Dover, Del.) gained exclusive, worldwide rights to BI 860585 from Boehringer Ingelheim GmbH (Ingelheim, Germany). Response from Xynomic Business Development Manager Angela Fung told BioCentury that Xynomic will pay Boehringer up to $800...
BioCentury | Dec 4, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Analysis of the copy numbers of mutant and wild-type alleles of oncogenes could help predict response to cancer therapies targeting those oncogenes. The method involves: performing genome-wide, allele-specific copy number...
BioCentury | Nov 30, 2018
Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
Items per page:
1 - 10 of 406